In clinical trials, the Johnson & Johnson vaccine appears to be 66% effective at preventing moderate to severe cases of COVID-19 — compared to about 95% for Moderna and Pfizer. That has some people wondering if they should avoid the Johnson & Johnson vaccine. Absolutely not, says Dr. Ashish Jha, dean of the Brown University School of Public Health. Read More
The study was conducted in the U.S., Latin America and South Africa. The vaccine did better at preventing disease in the U.S. – 72% — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%. Read More
The company said demand has declined "fueled by misinformation around the safety of the product and a constant barrage of litigation advertising." Lawsuits allege the powder causes cancer. Continue Reading Johnson & Johnson Stops Read More
Confronted with a torrent of lawsuits across the U.S., several major drug companies are in discussions with authorities to resolve thousands of opioid-related suits filed against them. A government source close to the negotiations tells NPR that Purdue Pharma, Johnson & Johnson, Endo International and Allergan are looking to cut deals. Read More